An interventional study of Virtual Reality + Conventional Physiotherapy and Conventional Physiotherapy in Duchenne Muscular Dystrophy (DMD) and Virtual Reality, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Istanbul University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Muscular Dystrophy, Duchenne with a site in Turkey — 15 open to participants now, 19 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · Turkey.
Among the 68 studies in Muscular Dystrophy, Duchenne with a site in Turkey, this one is the 21st largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, reaches primary completion later than 13 of the 18 other live ones, and was the 62nd registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →15 of the 68 studies in Muscular Dystrophy, Duchenne with a site in Turkey are open now. Recruiting first, the newest first:
Antalya Training and Research Hospital · Sites in Turkey
Ages 7–18 · Men only
Başak Çağla Arslan · Sites in Turkey
Ages 13–18 · Men only
Lokman Hekim Üniversitesi · Sites in Turkey
Ages 5–15 · Healthy volunteers
Gülsena Utku · Sites in Turkey
Ages 5–12 · Men only
NS Pharma, Inc. · Sites in Turkey, United States, Australia and 4 more countries
Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 18 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 9
First in 2010; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 36 across the 41 interventional studies, 41 across the 26 observational. Of the 42 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 68 have an industry lead sponsor. The 10 most frequent:
Istanbul University is the lead sponsor of 514 studies on the registry; 78 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Istanbul University has 2 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
6 of the studies in Muscular Dystrophy, Duchenne with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892196Antalya Training and Research HospitalDoes Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? | 2026-11-30 |
| NCT07821125Lokman Hekim UniversityUrotherapy Education for Families of Children With Duchenne Muscular Dystrophy | 2026-12-01 |
| NCT06887491Lokman Hekim UniversityThe Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled Trial | 2027-01-15 |
| NCT07039799Istanbul UniversityThe Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy | 2027-02-15 |
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
Add all 6 to your calendar (.ics) → With an account.
Among the 68 studies in Muscular Dystrophy, Duchenne with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of fully immersive virtual reality (VR) applications on upper extremity (UE) functions in individuals diagnosed with Duchenne Muscular Dystrophy (DMD). DMD is a progressive neuromuscular disorder that leads to muscle weakness and loss of function, including the upper limbs, which are essential for daily activities and independence.
In this randomized controlled trial, 36 participants with DMD will be divided into two groups: a control group receiving conventional physiotherapy and an intervention group receiving the same physiotherapy program (excluding upper extremity exercises) combined with VR-based exercises. The VR games will be designed specifically to improve shoulder, elbow, wrist, and hand functions and will be delivered using Meta Quest 3 headsets with hand-tracking capabilities.
Both groups will receive therapy twice a week for 8 weeks. Assessments will be conducted before and after the intervention, and at follow-up, using validated tools to measure UE function, grip strength, fine motor skills, trunk control, fatigue, quality of life, and participation in daily activities.
The study aims to explore innovative rehabilitation strategies for DMD and contribute to improving the independence and quality of life of affected individuals.
Duchenne Muscular Dystrophy (DMD) is a progressive genetic disorder characterized by the absence of dystrophin, leading to degeneration and weakness of skeletal muscles. While early clinical symptoms primarily affect the lower extremities, upper extremity (UE) dysfunction significantly impacts daily life and independence, especially as the disease progresses and ambulation is lost. Despite its clinical relevance, upper limb rehabilitation remains underrepresented in current treatment strategies, and there is a clear need for innovative and engaging approaches tailored to this population.
Virtual reality (VR) offers an interactive and motivating rehabilitation environment, enabling repetitive task-oriented training in a controlled and safe setting. In recent years, fully immersive VR systems have gained attention in pediatric neurorehabilitation due to their potential to improve motor function while increasing patient engagement and compliance. However, research on the application of VR in DMD, particularly targeting upper limb function, remains limited.
This study is a randomized controlled trial designed to evaluate the impact of immersive VR-based rehabilitation on UE functions in children and adolescents with DMD. A total of 36 participants will be randomly assigned to either an intervention group receiving a combination of conventional physiotherapy and VR-based upper extremity training, or a control group receiving only conventional physiotherapy including aerobic, strengthening, stretching, breathing, posture, and functional exercises.
The VR program includes three custom-developed therapeutic games targeting shoulder, elbow, wrist, and hand movements. These games will be administered using the Meta Quest 3 headset with hand-tracking technology, allowing participants to interact with the virtual environment without additional controllers. The games will be adapted to each participant's functional level, with adjustable difficulty and personalized content. Sessions will take place twice weekly for 8 weeks, with each session lasting approximately 40 minutes.
Outcome measures include standardized clinical tools to assess upper extremity performance (e.g., PUL 2.0, pinch strength, pegboard test), fine motor skills, trunk control, fatigue, health-related quality of life, and participation levels. Usability and potential side effects of VR will also be evaluated through questionnaires and observation during sessions.
Prior to the randomized controlled trial, a preliminary formative usability evaluation was conducted with five individuals with Duchenne muscular dystrophy to assess the feasibility, usability, comfort, and interaction characteristics of the VR rehabilitation games. Feedback obtained from quantitative usability measures, observation, and qualitative user comments was used to refine game mechanics, interaction timing, difficulty progression, hand-tracking sensitivity, and overall gameplay experience before implementation in the main trial.
The findings of this trial are expected to contribute to the evidence base supporting VR as a feasible and effective tool for enhancing upper limb function in children with DMD, and to guide future integration of digital technologies in neuromuscular rehabilitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this group will receive a conventional physiotherapy program excluding upper extremity (UE) functional exercises. In addition, they will participate in immersive virtual reality (VR)-based rehabilitation sessions using a Meta Quest 3 headset. The VR intervention includes three custom-designed games targeting shoulder, elbow, wrist, and hand movements. These sessions will be administered twice weekly for 8 weeks, with each session lasting approximately 40 minutes. Games are tailored to each participant's functional level and designed to enhance motivation, participation, and UE motor function.
Behavioral: Virtual Reality + Conventional Physiotherapy · Other: Formative Usability Evaluation of the VR Rehabilitation Platform
Participants in this group will receive a conventional physiotherapy program including aerobic exercises, strengthening, stretching, posture training, breathing exercises, and functional upper extremity exercises. The sessions will be delivered by physiotherapists twice per week for 8 weeks, each lasting approximately 40 minutes. No virtual reality intervention will be provided in this group.
Behavioral: Conventional Physiotherapy
This intervention involves the use of fully immersive virtual reality (VR) applications delivered through the Meta Quest 3 headset, integrated with hand-tracking technology. Participants engage in three custom-designed VR games aimed at improving shoulder, elbow, wrist, and hand functions. The games are tailored to individual functional levels and include progressive difficulty. Sessions are conducted twice per week for 8 weeks, each lasting approximately 40 minutes, under the supervision of a physiotherapist. This intervention is combined with conventional physiotherapy (excluding functional upper extremity exercises).
This intervention consists of a standard physiotherapy program for individuals with Duchenne Muscular Dystrophy. It includes aerobic exercises, strengthening exercises, stretching routines, postural training, respiratory exercises, and functional upper extremity exercises. The sessions are delivered by a physiotherapist twice weekly for 8 weeks, with each session lasting approximately 40 minutes.
Before initiation of the randomized controlled trial, the VR rehabilitation platform underwent a preliminary formative usability evaluation involving five individuals with Duchenne muscular dystrophy (DMD). During this pre-evaluation phase, perceived usability, enjoyment, ease of use, and potential VR-related discomfort associated with the VR games were assessed using standardized outcome measures, including the System Usability Scale (SUS), the enjoyment subscale of the Game User Experience Satisfaction Scale (GUESS), and the Virtual Reality Sickness Questionnaire (VRSQ). In addition, qualitative user feedback was collected through open-ended questions regarding gameplay experience, perceived difficulties, and suggestions for improvement. Findings from this formative evaluation were used to optimize gameplay mechanics, interaction design, and overall system usability prior to implementation of the randomized controlled trial.
Performance of the Upper Limb (PUL 2.0) Score
A clinician-reported outcome measure designed to assess upper limb motor performance in individuals with Duchenne Muscular Dystrophy. It includes tasks at shoulder, mid-level, and distal levels.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Pediatric Quality of Life Inventory - Neuromuscular Module (PedsQL-NM)
A participant and parent-reported instrument assessing health-related quality of life in pediatric patients with neuromuscular disorders.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Participation and Environment Measure for Children and Youth (PEM-CY)
A parent-reported measure assessing children's participation and environmental support at home, school, and in the community.
Time frame: Baseline, 8 weeks, and 4-week follow-up
ABILHAND-Kids Manual Ability Scale
The ABILHAND-Kids is a parent-reported questionnaire designed to measure manual ability in children with upper limb impairments. It contains 21 items scored based on perceived difficulty. Minimum score: 0; Maximum score: 42. Higher scores indicate better manual ability.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Pinch Grip Strength Using Jamar Pinch Gauge
Measurement of lateral pinch strength in kilograms using a standardized hand-held dynamometer.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Nine-Hole Peg Test (9HPT)
A timed performance test evaluating fine motor dexterity by measuring the time taken to place and remove pegs using each hand.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Trunk Control Measurement Scale (TCMS)
The Trunk Control Measurement Scale (TCMS) is a standardized clinical tool used to assess trunk control in children with neuromotor disorders. It evaluates both static and dynamic sitting balance through 15 tasks grouped into three subscales: static sitting balance, selective movement control, and dynamic reaching.Minimum score: 0; Maximum score: 58. Higher scores indicate better trunk control.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Multidimensional Fatigue Scale (PedsQL Fatigue Scale)
The Pediatric Quality of Life (PedsQL) Multidimensional Fatigue Scale is a standardized questionnaire used to assess fatigue in children and adolescents. It includes 18 items covering three subscales: General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue. Each item is scored on a 5-point Likert scale and then linearly transformed to a 0-100 scale. Minimum score: 0; Maximum score: 100. Higher scores indicate better functioning.
Time frame: Baseline, 8 weeks, and 4-week follow-up
Timed Upper Extremity Functional Tasks (e.g., T-shirt On/Off, Coin Pick-Up)
A set of timed performance tasks evaluating the duration of functional UE activities.
Time frame: Baseline, 8 weeks, and 4-week follow-up
System Usability Scale - Turkish Version (SUS-TR)
The System Usability Scale - Turkish Version (SUS-TR) is the Turkish-adapted version of the System Usability Scale, a 10-item questionnaire used to evaluate the perceived usability of a system or product. Each item is rated on a 5-point Likert scale and converted to a composite score ranging from 0 to 100. Minimum score: 0; Maximum score: 100. Higher scores indicate better usability.
Time frame: Post-intervention (8 weeks)
The System Usability Scale
The System Usability Scale - Turkish Version (SUS-TR) is the Turkish-adapted version of the System Usability Scale, a 10-item questionnaire used to evaluate the perceived usability of a system or product. Each item is rated on a 5-point Likert scale and converted to a composite score ranging from 0 to 100. Minimum score: 0; Maximum score: 100. Higher scores indicate better usability.
Time frame: Day 1 (Immediately after a single VR session)
The Game User Experience Satisfaction Scale - Enjoyment Subscale (GUES-Enjoyment)
The Game User Experience Satisfaction Scale - Enjoyment Subscale (GUES-Enjoyment) is a subscale used to assess the level of enjoyment and engagement experienced during gameplay. Items are rated on a 7-point Likert scale, with higher scores reflecting greater enjoyment and satisfaction related to the gaming experience. Higher scores indicate greater perceived enjoyment.
Time frame: Day 1 (Immediately after a single VR session)
Perceived Ease of Use
Perceived Ease of Use will be assessed using a 5-point Likert-type rating scale evaluating how easy participants perceive the VR games to use and interact with. Minimum score: 1; Maximum score: 5. Higher scores indicate greater perceived ease of use.
Time frame: Day 1 (Immediately after a single VR session)
The Virtual Reality Sickness Questionnaire (VRSQ)
The Virtual Reality Sickness Questionnaire (VRSQ) is a self-report questionnaire used to evaluate VR-related discomfort symptoms experienced during or after exposure to immersive virtual environments. The questionnaire assesses symptoms such as dizziness, nausea, eye strain, and disorientation. Higher scores indicate greater VR-related discomfort and symptom severity.
Time frame: Day 1 (Immediately after a single VR session)
Plan to share: No — Individual participant data (IPD) will not be shared due to the inclusion of a pediatric and vulnerable population diagnosed with Duchenne Muscular Dystrophy (DMD). To protect participants' privacy and ensure compliance with ethical standards and data protection regulations, data sharing is not planned.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 18 months is close to that.
Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →